Current trends in highly active anti-retroviral therapy in an anti-retroviral therapy centre attached to a remote government medical college of Maharashtra, India: a retrospective study

Pravin S. Rathod, Praveenkumar T. Patil, Rekha P. Lohar, A. W. Patil


Background: Highly active anti-retroviral therapy (HAART) became the keystone of national AIDS program. There is lack of awareness and inadequate training about drug safety monitoring among health care professionals in India. Hence, the present study was carried out to study current trends in HAART and pattern of associated adverse drug reactions.

Methods: A retrospective observational study was conducted at an anti-retroviral therapy (ART) Centre. A total of 151 HIV/AIDS Patients (old and new cases) receiving HAART during July 2015 to December 2015 were randomly included in the study. Causality and severity assessment of adverse drug reactions (ADRs) was done by using Naranjo’s ADR causality scale and modified Hartwig and Siegel scale respectively. The data was computed using MS Excel and descriptive results were expressed as counts and percentages. The study was approved by institutional ethics committee.

Results: The prevalence of HIV/AIDS infection was higher in adult males (51.66%). Zidovudine+lamivudine+nevirapine (ZLN) was the most commonly prescribed HAART combination. Out of 132 ADRs reported, 76.52% of the ADRs were related to haematological system and ZLN was the commonest combination causing ADRs. 90.91% ADRs belong to possible category on causality assessment and 68.94% of the ADRs were of moderate severity. Tuberculosis (28.47%) was the commonest diagnosed opportunistic infection among the HIV/AIDS patients.

Conclusions: The prescribing pattern of HAART regimens was in accordance with national guidelines for antiretroviral therapy. We recommend a pharmacovigilance system for sustainable management of ADRs in HIV/AIDS patients as we found under reporting of ADRs.


HIV/AIDS,HAART,ADRs,Opportunistic infections

Full Text:



Oreagba IA, Usman SA, Olayemi SO, Oshikoya KA, Opanuga O, Adeyemo TA. Pharmaco epidemiology of antiretroviral drugs in a teaching Hospital In Lagos, Nigeria. Ghana Medical Journal. 2014;48:94-203.

World Health Organization [home page on internet] 2008. Available at Accessed 18 March 2016.

Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report UNAIDS Report on the Global AIDS Epidemic-2010. Geneva: UNAIDS; 2010.

Bhuvana KB, Hema NG, Sangeetha. A prospective observational study of adverse drug reactions to antiretroviral therapy: type and risk factors in a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2014;3:380-4.

Prakashraju GK, Chowta MN, Rather ZA, Mubeen F. The Pattern of the initial anti-retroviral drug regimens in HIV Patients at a tertiary care hospital. Journal of Clinical and Diagnostic Research. 2012;6:1178-80.

Nadkar MY, Bajpai S. Antiretroviral therapy: toxicity and adherence. J Assoc Physicians India. 2009;57:375-6.

Divakar B, Mistry SD, Kantharia ND, Mamtarani. The study of adverse drug reactions (ADR’s) in HIV patients taking highly active antiretroviral therapy in ART centre, NCH, Surat, India. Int J Med Pharm Sci. 2012;03:9-18.

Monforte AA, Lepri AC, Rezza G, Pezzoti P, Antinori A, Phillips AN et al. Insights into the reasons for discontinuation of the firstly highly active anti retro viral therapy (HAART) regimen in a cohort of antiretroviral naive patients: Italian cohort of antiretroviral naove patients. AIDS. 2000;14:499-507.

Patel NM, Vaniya HV, Agrawal JM, Balat JD, Singh AP, Trivedi HR. Adverse drug reaction monitoring on antiretroviral therapy in human immunodeficiency virus patients in a tertiary care hospital. Int J Basic Clin Pharmacol. 2015;4:907-11.

Zaki SA. Adverse drug reaction and causality assessment scales. Lung India. 2011;28:152-3.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

Kanha MM, Sharmila SK. Comparative study of adverse drug reactions of two antiretroviral regimens (zidovudine+lamivudine+nevirapinevsstavudine+lamivudine+ nevirapine) In Hiv/Aids Patients. Journal of Dental and Medical Sciences. 2015;14:36-44.

Kapadia JD, Desai CK, Dikshit RK, Solanki MN, Shah AN. A study of utilization pattern, efficacy and safety of drugs prescribed for opportunistic infections in human immunodeficiency virus infected patients. Int J Med Public Health. 2014;4:200-9.

Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3(1):62-7.

Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVS) incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12(7).

Jiyo C, Suthar SD, Dholaria NK, Chavda DA, Bhansali NB, Gosai TR, et al. Drug utilization study of HIV positive patients registered with antiretroviral therapy centre of a tertiary care hospital. J Clin Exp Res. 2013;1:12-9.

Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, Lim PL. Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the treat Asia HIV observational database (TAHOD). AIDS Res Ther. 2007;4:18.

Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. Indian J Med Sci. 2010;64:245-52.

Reddy KAV, Lihite RJ, Lahkar M, Choudhury U, Swaroop K. Baruah SK. A Study on adverse drug reactions in HIV infected patients at a art centre of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res. 2013;6:102-4.

Rajesh R, Vidyasagar S, Nandakumar K. Highly active antiretroviral therapy induced adverse drug reactions in Indian human immunodeficiency virus positive patients. Pharmacy Practice (Internet). 2011;9(1):48-55.

Dabla V, Gupta AK and Singh I. Spectrum of opportunistic infections among HIV seropositive patients in Delhi region-a study by Delhi state AIDS control society. J Med Disord. 2015;3:1.